diabetic macular edema,retinal vein occlusion,wet age-related macular degeneration
Conditions
Interventions
DME anti-VEGF Group:NA
nAMD anti-VEGF Group:NA
RVO anti-VEGF Group:NA
RVO-Dexamethasone sustained release Group:NA
Sponsors
Dalian NO.3 People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Intravitreal injections of anti-VEGF drugs / dexamethasone sustained-release agents in our hospital (the injected drugs are ranibizumab / conbercept / aflibercept / odevixibat), anti-VEGF drugs should be injected at least once a month for three consecutive times; dexamethasone sustained-release drugs do not need to be injected monthly, but only as needed.
Exclusion criteria
Exclusion criteria: 1. Within the past three months, there has been a history of ocular surgery or laser photocoagulation treatment for the retina; 2. Within the past three months, there has been a history of systemic or local glucocorticoid treatment; 3. Suffering from other ocular diseases that cause changes in the fundus, including polypoidal choroidal vasculopathy, glaucoma, retinal vasculitis, etc. 4. The refractive medium is significantly turbid, resulting in poor quality of OCT images (such as severe cataract, thick retinal hemorrhage, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The best corrected visual acuity;central retinal thickness;area and volume of fluid accumulation in the retina;number of retinal high reflex points;length of inner retinal disorder;subfoveal choroid thickness;retinal and choroid biological markers; | — |
Countries
China
Contacts
Public ContactQi Yuanyuan
Dalian NO.3 People's Hospital
Outcome results
None listed